{"filing":{"accession_number":"0001628280-26-057112","cik":"0001725160","ticker":"ZNTL","company_name":"Zentalis Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-13","primary_document":"zntl-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725160/000162828026057112/zntl-20260813.htm"},"events":[{"id":27897,"run_id":25474,"accession_number":"0001628280-26-057112","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Zentalis entered into an underwriting agreement to issue and sell 23,000,000 shares of common stock at $3.50 per share, with an additional 3,450,000-share option granted to underwriters. This is a registered public offering of equity securities generating approximately $75.1 million in net proceeds. While technically registered (via Form S-3), the scale and dilutive impact to existing shareholders make this a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29611,"accession_number":"0001628280-26-057112","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Zentalis entered into an underwriting agreement to issue and sell 23,000,000 shares of common stock at $3.50 per share, with an additional 3,450,000-share option granted to underwriters. This is a registered public offering of equity securities generating approximately $75.1 million in net proceeds. While technically registered (via Form S-3), the scale and dilutive impact to existing shareholders make this a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:21:52.166878+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29611,"accession_number":"0001628280-26-057112","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Zentalis entered into an underwriting agreement to issue and sell 23,000,000 shares of common stock at $3.50 per share, with an additional 3,450,000-share option granted to underwriters. This is a registered public offering of equity securities generating approximately $75.1 million in net proceeds. While technically registered (via Form S-3), the scale and dilutive impact to existing shareholders make this a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:21:52.166878+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-08-14"}]}